Trials
1 active
13 in total
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “TAS-102 will be administered orally twice daily at a dose calculated based on body surface area (BSA) within 1 hour after morning and evening meals for 5 days, a week with 2 days rest for 2 weeks, followed by a 14-day rest, repeated every 4 weeks.”In the company’s words, NCT04999761 on ClinicalTrials.gov
- Tested for
- Advanced or Metastatic Solid Tumor, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Non-small Cell Lung Cancer, Gastric Cancer, Alveolar Soft Part Sarcoma, Esophageal Cancer, Head and Neck Cancer and 1 more
- Main trialPhase 1
- “This is a phase 1, non-randomized open-label, multicenter platform study designed to evaluate the tolerability and safety of AB122 in patients with malignancies specified in each cohort.”In the company’s words, NCT04999761 on ClinicalTrials.gov
- Other names
- Lonsurf · Oral Solution
Other drugs for Advanced or Metastatic Solid Tumor
- PembrolizumabMerck & Co. · Phase 3
- EIK1001Eikon Therapeutics · Phase 2/3
- QL2107Qilu Pharmaceutical · Phase 3
- IFx-Hu2.0TuHURA Biosciences, Inc. · Phase 2/3
- FutibatinibTaiho · Phase 2/3
- MB11mAbxience Research S.L. · Phase 3
Coming up1
- Jun 2027Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials13
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Recruiting | Jun 2027 | AB122 Platform Study | |
| Phase 3Completed | 31 Jan 2014 | Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies | |
| Phase 3Completed | 30 Apr 2018 | Study of TAS-102 or Placebo Plus BSC in Patients With Metastatic Gastric Cancer | |
| Phase 2Terminated | Jun 2014 | A Phase 2 Study Comparing TAS-102 Versus Topotecan or Amrubicin to Treat Small Cell Lung Cancer Following Platinum-Based Chemotherapy | |
| Phase 2Completed | Aug 2017 | A Study Evaluating TAS-102 Plus Nivolumab in Patients With MSS CRC | |
| Phase 1Completed | Oct 2013 | Study Comparing the Pharmacokinetics of FTD as a Component of TAS-102 With FTD Alone | |
| Phase 1Completed | Aug 2014 | Study to Evaluate the Cardiac Safety of TAS-102 in Patients With Advanced Solid Tumors | |
| Phase 1Completed | Nov 2014 | Study of the Mass Balance of Oral FTD and TPI as Components of TAS-102 in Patients With Advanced Solid Tumors | |
| Phase 1Completed | Aug 2015 | Study Comparing the Bioavailability of TAS-102 Tablets to an Oral Solution Containing Equivalent Amounts of FTD and TPI | |
| Phase 1Completed | Oct 2015 | A Phase I Study of TAS-102 in Solid Tumors | |
| Phase 1Completed | Jun 2016 | A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Hepatic Impairment | |
| Phase 1Completed | Sep 2017 | A Phase I Study of TAS-102 in Patients With Advanced Gastrointestinal Tumors. | |
| Phase 1Completed | 19 Jun 2019 | A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Renal Impairment |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026